Charles A. Deignan
2022
In 2022, Charles A. Deignan earned a total compensation of $876K as Chief Financial Officer at Clearside Biomedical, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $138,250 |
|---|---|
| Option Awards | $237,791 |
| Salary | $388,650 |
| Stock Awards | $101,288 |
| Other | $10,050 |
| Total | $876,029 |
Deignan received $388.7K in salary, accounting for 44% of the total pay in 2022.
Deignan also received $138.3K in non-equity incentive plan, $237.8K in option awards, $101.3K in stock awards and $10.1K in other compensation.
Rankings
In 2022, Charles A. Deignan's compensation ranked 3,318th out of 5,760 executives tracked by ExecPay. In other words, Deignan earned more than 42.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,318 out of 5,760 | 42nd |
Division Manufacturing | 1,869 out of 3,136 | 40th |
Major group Chemicals And Allied Products | 890 out of 1,422 | 37th |
Industry group Drugs | 833 out of 1,323 | 37th |
Industry Pharmaceutical Preparations | 607 out of 969 | 37th |
Source: SEC filing on April 28, 2023.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2022.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019